Claims for Patent: 8,889,186

Summary for Patent: 8,889,186

Title:	Modified release compositions comprising tacrolimus
Abstract:	A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.
Inventor(s):	Holm; Per (Vanlose, DK), Norling; Tomas (Lyngby, DK)
Assignee:	Veloxis Pharmaceuticals A/S (Horsholm, DE)
Application Number:	14/079,466
Patent Claims:	1. A method for suppressing a rejection reaction by transplantation of an organ in a patient, the method comprising orally administering to the patient a therapeutically effective amount of one or more solid extended release pharmaceutical compositions, each solid extended release pharmaceutical composition comprising tacrolimus and one or more modifying release agents, wherein the pharmaceutical composition provides a W.sub.50 (the time where the plasma concentration is 50% or more of C.sub.max) of at least 10 hours in the patient. 2. The method of claim 1, wherein the transplanted organ is a kidney. 3. The method of claim 1, wherein the C.sub.max resulting from oral administration of the composition is reduced compared to administration of the same dose from an immediate release tacrolimus pharmaceutical composition. 4. The method of claim 1, wherein the pharmaceutical composition provides a C.sub.max that is at most about 80% of that of C.sub.max for a similar dose of Prograf capsules (U.S. New Drug Application No. 050708). 5. The method of claim 1, wherein the extended release pharmaceutical composition is designed to substantially avoid CYP3A4 metabolism in the gastrointestinal tract upon oral administration. 6. The method of claim 1, wherein the extended release pharmaceutical composition has a C.sub.diff, when orally administered, of 80 or less, relative to a C.sub.diff of 100 for a similar dose of Prograf capsules (U.S. New Drug Application No. 050708). 7. The method of claim 1, wherein the extended release pharmaceutical composition provides a zero order release profile. 8. The method of claim 1, wherein the oral administration of the composition results in a plasma concentration of about 5 ng/mL to about 20 ng/mL for at least about 24 hours. 9. The method of claim 1, wherein the pharmaceutical composition provides an AUC.sub.fed/AUC.sub.fasted of at least 0.9. 10. The method of claim 1, wherein the composition releases at most 62% of the tacrolimus in the composition within 15 hours when subjected to an in vitro dissolution test using USP Paddle method at a rotation speed of 50 rpm in a 900 mL aqueous dissolution medium with 0.005% hydroxypropylcellulose which has been adjusted to pH 4.5. 11. The method of claim 10, wherein at most 60% w/w of the tacrolimus in the composition is released within 15 hours, when subjected to the in vitro dissolution test. 12. The method of claim 10, wherein at most 50% w/w of the tacrolimus in the composition is released within 15 hours, when subjected to the in vitro dissolution test. 13. The method of claim 1, wherein the composition is in the form of a compressed tablet. 14. A method for suppressing a rejection reaction by transplantation of an organ in a patient, the method comprising orally administering once daily to the patient a therapeutically effective amount of one or more solid extended release pharmaceutical compositions, each solid extended release pharmaceutical composition comprising tacrolimus and one or more modifying release agents, wherein the pharmaceutical composition provides (i) a W.sub.50 (the time where the plasma concentration is 50% or more of C.sub.max) of at least 10 hours in the patient and (ii) a C.sub.max that is at most about 80% of that of C.sub.max for a similar dose of Prograf capsules (U.S. New Drug Application No. 050708). 15. A method for suppressing a rejection reaction by transplantation of an organ in a patient, the method comprising orally administering to the patient a therapeutically effective amount of one or more solid extended release pharmaceutical compositions, each solid extended release pharmaceutical composition comprising tacrolimus particles, wherein (i) the particles contain tacrolimus dispersed or dissolved in a vehicle, (ii) the particles have a d.sub.gw of from about 100 to about 700 .mu.m, and (iii) the pharmaceutical composition provides a W.sub.50 (the time where the plasma concentration is 50% or more of C.sub.max) of at least 10 hours. 16. The method of claim 15, wherein the pharmaceutical composition provides a C.sub.max that is at most about 80% of that of C.sub.max for a similar dose of Prograf capsules (U.S. New Drug Application No. 050708). 17. The method of claim 15, wherein the composition releases at most 62% of the tacrolimus in the composition within 15 hours when subjected to an in vitro dissolution test using USP Paddle method at a rotation speed of 50 rpm in a 900 mL aqueous dissolution medium with 0.005% hydroxypropylcellulose which has been adjusted to pH 4.5. 18. The method of claim 17, wherein at most 60% w/w of the tacrolimus in the composition is released within 15 hours.